IBOHealthcare · Biotechnology

IBO Stock Forecast: Impact BioMedical, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026

$3.80

−5.47% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 21 Oct 2026 — in the weakest quartile.

Market cap

$27.9M

Ticker Nerd rank

23/ 100

Median analyst target

—

Analysts covering

—

Revenue$3K−57.1% y/y

Operating income−$702K

Net income−$700K

Free cash flow$470K

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+20.3%

−43.1%

YTD

−40.6%

−48.4%

From 52W high

−61.5%

From 52W low

+41.8%

$2.68

$9.87

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

IBO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Impact BioMedical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Oct 2026

23/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Growth

Issuance

Momentum

Accruals

Revisions

Quality

Volatility

Value

Size (84): Smaller than most of the companies we track.

Value (12): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IBO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IBO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

IBO appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
The AI build-out, every Wednesday: how AI stocks did, part by part.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

IBO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Impact BioMedical, Inc. returned −48.4% against +17.0% for the S&P 500, dividends included.

IBO vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IBO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Impact BioMedical, Inc. (IBO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.3×
Price / sales: 797.6×
Price / book: 2.6×
EV / EBITDA: −7.9×

Growth & margins

Revenue growth (YoY): −57.1%
Earnings growth (YoY): −57.1%
Gross margin: 66.7%
Operating margin: −23400.0%
Net margin: 2260.0%

Returns & dividend

Return on equity: 23.5%
Return on assets: −17.8%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Impact BioMedical, Inc. (IBO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Impact BioMedical, Inc. has a market value of $27.9M and an enterprise value of $31.2M.
Revenue in the twelve months to 30 June 2026: $35K. The latest quarter shrank 57.1% year on year.
Net income over the same four quarters: $776K, a 2217.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$508K.
Shares outstanding: 107.8M.
Trailing P/E: 0.3×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Impact BioMedical, Inc. employs 2 people — $18K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Oct 2026

Data provided by Twelve Data

Peers

IBO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
IBOImpact BioMedical, Inc.	$27.9M	23
GRDXGridAI Technologies Corp.	$34.7M	14
IRLAIRulya Therapeutics, Inc.	$33.9M	31
BCTXBriaCell Therapeutics Corp.	$33.7M	—
CRVOCervoMed, Inc.	$35.4M	32
EYPTEyePoint, Inc.	$35.6M	12
CELUCelularity, Inc.	$33.1M	30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Impact BioMedical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IBO news & analysis

Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited)

GlobeNewsWire · 16 Sept 2026neutral

Impact Biomedical Inc. announced that a Form F-4 registration statement was filed with the SEC on September 10, 2026, by Zoar Limited in connection with the previously announced business combination involving PubCo and Zoar Labs Limited (f/k/a Dr. Ashley's Bio Labs Limited). The filing includes Impact's preliminary proxy statement and is available on the SEC's website under the name "Zoar Limited."

Why it matters — This filing marks a regulatory step forward in the proposed merger between Impact Biomedical and Zoar Ltd., which IBO shareholders will need to monitor as the transaction progresses.

CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)

GlobeNewsWire · 15 Sept 2026neutral

Impact Biomedical Inc issued a corrected press release stating that, after its planned 1-for-12.62 reverse stock split, stockholders will receive one share of Zoar Limited for every one share of Impact Common Stock held immediately prior to the merger's effective time. This corrects the exchange ratio (previously stated as one Zoar share for every four Impact shares) in its September 11, 2026 release, with no other changes made.

Why it matters — The corrected exchange ratio is material to IBO shareholders because it clarifies how their shares will convert in the pending merger with Zoar Limited following the reverse split.

Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley's Ltd.

GlobeNewsWire · 11 Sept 2026neutral

Impact BioMedical Inc. announced that its Board of Directors approved a 1-for-12.62 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on September 23, 2026. The shares will continue trading on the NYSE American under the ticker "IBO" with a new CUSIP number, as the company pursues completion of its merger with Zoar Ltd. (previously Dr. Ashley's Ltd.).

Why it matters — IBO watchers would care because the reverse stock split is a structural corporate action tied to the company's progress toward completing its pending merger with Zoar Ltd.

FAQ

Frequently asked questions about IBO stock

How does Ticker Nerd's model rank IBO?

As at 21 Oct 2026, Impact BioMedical, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (84 of 100).

What is the IBO stock forecast for 2030?

No analyst covering Impact BioMedical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IBO are extrapolating price history, which says nothing about the business.

How has IBO stock performed over the past year?

Impact BioMedical, Inc. returned -48.4% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Impact BioMedical, Inc. do?

Impact BioMedical Inc. is a biotechnology company focused on discovering, validating, and commercializing science-based products and technologies for human healthcare and wellness.

What is the latest news on IBO?

The most recent item we track (GlobeNewsWire, 16 Sept 2026): "Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited)". Impact Biomedical Inc. announced that a Form F-4 registration statement was filed with the SEC on September 10, 2026, by Zoar Limited in connection with the previously announced business combination involving PubCo and Zoar Labs Limited (f/k/a Dr. Ashley's Bio Labs Limited). The filing includes Impact's preliminary proxy statement and is available on the SEC's website under the name "Zoar Limited."

Company

About Impact BioMedical, Inc.

Impact BioMedical Inc. is a biotechnology company focused on discovering, validating, and commercializing science-based products and technologies for human healthcare and wellness. Its current business spans specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and direct-to-consumer wellness offerings. The company works through licensing, co-development, joint ventures, and other partnerships to advance technologies aimed at drug discovery and the prevention, inhibition, and treatment of neurological, oncologic, immune-related, and inflammatory conditions. It also develops products for broader wellness applications, including over-the-counter and consumer health categories. Based in Houston, Texas, Impact BioMedical Inc. plays a role in turning intellectual property and research-driven concepts into marketable healthcare solutions for pharmaceutical, consumer goods, and other industry partners.

CEO Mr. Frank D. Heuszel Esq., J.D. · 2 employees · United States · https://www.impactbiomedinc.com